Executive Summary
Key Takeaways
- Stop the distribution of non-FDA-approved compounded GLP-1 drugs to avoid federal seizures and injunctions: The FDA announced it will target companies marketing these products as alternatives to branded medications. Source
- Audit payer contracts for anti-steering and all-or-nothing provisions: The DOJ and Ohio Attorney General sued OhioHealth, alleging these terms prevent competition and drive up consumer costs. Source
- Monitor state-level AI restrictions for insurance decisions despite federal preemption efforts: States like Arizona and Texas are passing laws to limit automated claim denials, creating a legal battle over federal executive oversight. Source
Key Themes
Major trends and developments identified from this week's coverage
Price Transparency and Market Friction
Regulators are dismantling information silos and price secrecy, though KFF data suggests hospital spending still drove 40% of national health expenditure growth through 2024.
3 articles
Pharmaceutical Supply Chain Oversight
The federal government is targeting high-cost drug supply chains, moving to restrict compounded GLP-1s while experimenting with 340B rebate models to control ceiling prices.
2 articles
AI and Standards Evolution
Standards are evolving from FHIR profiles toward "Conversational Interoperability" (COIN) as AI clinicians begin handling high-volume consults with 99.2% accuracy in pilots.
2 articles
Key Players
Top companies, people, and technologies mentioned this week
3 articles
Appointed Mehmet Oz to lead the Centers for Medicare & Medicaid Services. (+2 more)
7 articles
Issued cease-and-desist orders for deceptive drug ads and flagged Novo Nordisk for misleading Wegovy spots. (+6 more)
3 articles
The defendant in the CureIS case who had its motion to stay discovery denied. (+2 more)
4 articles
HHS Secretary who stated the policy makes it easier for companies to move away from petroleum-based colors. (+3 more)
3 articles
National newsroom producing the health journalism (+2 more)
4 articles
The agency responsible for the quarterly listing of program issuances. (+3 more)
4 articles
The agency issued a letter to industry regarding enforcement discretion for 'no artificial colors' claims. (+3 more)
2 articles
The federal agency that Mehmet Oz has been appointed to lead. (+1 more)
4 articles
FDA Commissioner who noted that calling natural colors 'artificial' was confusing for consumers. (+3 more)
2 articles
The CDC is leading the investigation into the multistate Salmonella outbreak linked to moringa capsules. (+1 more)
Regulatory & Policy Updates
FDA Restricts GLP-1 Active Ingredients for Compounding
Telehealth platforms and compounding pharmacies can no longer mass-market compounded GLP-1s as generics without risking FDA seizure of inventory.
CMS/MEDICAREHRSA Issues RFI on 340B Rebate Model Pilot
Manufacturers and covered entities should prepare for a potential shift from upfront 340B discounts to a rebate-based ceiling price implementation.
STATEEight States Introduce Laws to Ban Wage Garnishment for Medical Debt
Hospitals in states like Colorado may face new restrictions on collecting unpaid bills, with proposed caps on interest and garnishment set at 4% of net income.
Technology & Innovation
FDA Approves Novocure's Optune Pax for Pancreatic Cancer
Non-invasive "Tumor Treating Fields" (TTFields) devices are now moving into home-based cancer care settings, improving overall survival by two months in trials.
TEFCA Reaches 500 Million Record Exchanges
The rapid growth of national exchange networks is prompting the ASTP to introduce the HTI-6 rule to address anti-competitive behavior among large EHR vendors.
Alabama Proposes Robotic Ultrasounds for Rural Maternity Care
The $50B Rural Health Transformation Program is funding telerobotic solutions to address OB-GYN shortages, though clinical specialists debate their efficacy for high-risk pregnancies.
Market & Competitive Intelligence
Hims & Hers
PartnershipHims & Hers ceased selling compounded versions of Novo Nordisk's obesity medication following FDA and DOJ pressure regarding federal law violations.
OhioHealth
M&AThe DOJ filed a civil antitrust lawsuit against OhioHealth for allegedly using market power to impose anticompetitive contract terms on insurers.
Element Biosciences
Market EntryElement Biosciences launched a table-top DNA sequencer to deliver a $100 genome, significantly lowering the barrier for genomic clinical integration.
What to Watch
Wyoming Rural Health Perpetuity Fund
CMS decision expected Q2 2026Wyoming is seeking CMS approval to turn its Rural Health Transformation grants into a permanent investment endowment, a move that would bypass standard 2032 spending deadlines.
Clinical Utility of Multi-Cancer Early Detection (MCED)
Ongoing debate through 2026Grail's Galleri test failed a primary endpoint in a large NHS trial; watch for a pullback in Medicare coverage discussions for multi-cancer early detection tests.
Nebraska Medicaid Work Requirements Rollout
May 1, 2026Nebraska is set to become the first state to implement new Medicaid work requirements starting May 1, ahead of the federal 2027 mandate.
Editor's Picks
AI-recommended articles based on relevance and quality
Global COVID-19 Tracker | KFF
National Center for Advancing Translational Sciences; Notice of Closed Meeting
Hospital Spending Accounted for 40% of the Growth in National Health Spending Between 2022 and 2024 | KFF
Live Updates: Defiant Trump Says He’ll Work Around Supreme Court’s Tariff Ruling
Validation of the Simplified Chinese Clear Communication Index Using Diabetes Education Materials: Instrument Adaptation and Validation Study
Want personalized briefings?
Kelp creates AI-powered briefings tailored to your specific interests and sources. Get the insights that matter most to you.
Start Your Free Briefing